CJC-1295 2mg
Certificate of Analysis available
Mod GRF (1-29) (CJC-1295 no DAC)
CAS # 863288-34-0
Mol. weight 3367.95 g/mol
Formula C152H252N44O42
Identity
Manufacturer Generic Peptides
Active substance Modified GRF (1-29) — tetrasubstituted GHRH analog
Synonyms CJC-1295 no DAC, CJC-1295 without DAC, Mod GRF (1-29), Modified GHRH (1-29), D-Ala2-GHRH(1-29), Tetrasubstituted GRF (1-29)
Composition
Form Lyophilized powder
Purity ≥ 99% HPLC
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2
Product usage — Research only
- For in vitro testing and laboratory use only.
- Not for human or animal consumption.
- Bodily introduction is illegal.
- Handle only by licensed professionals.
- Not a drug, food, or cosmetic.
- Educational use only.
Native GHRH does not last long in blood. In human plasma it is cut within minutes by the enzyme dipeptidyl peptidase-4 (DPP-IV), which cleaves it at position 2. Modified GRF (1-29) is the answer peptide chemists arrived at: the same active 29-residue fragment with four amino acid substitutions that make it far more resistant to that enzyme. Same receptor, more stable molecule.
What Is Mod GRF (1-29)?
Modified GRF (1-29), also called CJC-1295 without DAC, is a synthetic 29-amino-acid GHRH analog. It's the first 29 residues of natural GHRH — the active fragment — with four targeted amino acid substitutions (D-Ala at position 2, Gln at position 8, Ala at position 15, Leu at position 27) that resist enzymatic degradation. Same active site that binds the GHRH receptor on pituitary somatotrophs. Just engineered for stability.
The "DAC" terminology gets confusing fast. In the original research, CJC-1295 meant this same modified 29-amino-acid peptide plus a Drug Affinity Complex tag — a lysine carrying a maleimidopropionyl group that binds serum albumin. In healthy adults that version had an estimated half-life of 5.8–8.1 days. Mod GRF (1-29) is the same peptide without the DAC tag: stabilized against enzymatic cleavage but without the albumin link. Two different research tools made from the same modified backbone. For the full comparison, see CJC-1295 DAC vs No DAC.
The Half-Life Decision That Defines Research Use
Why would researchers choose Mod GRF (1-29) over CJC-1295 DAC? Because they are designed for different questions. CJC-1295 DAC binds albumin and keeps the GHRH signal active for days; in healthy adults it raised the baseline GH level between pulses while the pulses themselves continued. Mod GRF (1-29) has no albumin linker, so it is expected to act briefly, as a short GHRH signal.
Its human pharmacokinetics, however, have never been reported in a peer-reviewed study; the short half-life figures quoted online are extrapolations. Researchers studying coordinated GH release often pair a short-acting GHRH analog with a ghrelin-receptor agonist such as Ipamorelin. For a side-by-side comparison with the DAC form, see CJC-1295 DAC vs No DAC.
What Serious Buyers Should Know
Here's what the marketing pages don't always make clear: Mod GRF (1-29) is essentially the same backbone as Sermorelin with the four stability substitutions added. Sermorelin is unmodified GRF 1-29; it was once FDA-approved (as Geref) and was later discontinued by its manufacturer, not for reasons of safety or effectiveness. Tesamorelin (Egrifta) is a different, full-length GHRH analog with a trans-3-hexenoic acid modification, FDA-approved for HIV-associated lipodystrophy. All three target the same receptor. Their pharmacokinetics differ.
The honest part: published human data on Mod GRF (1-29) as a standalone compound are essentially absent. A 2026 review in Frontiers in Endocrinology described "CJC-1295 without DAC" as essentially uncharacterised in the peer-reviewed human literature. The human studies often cited for it were done with the DAC version, which contains the same peptide plus the albumin linker. Our Mod GRF 1-29 research guide reviews what is and is not known.
Regulatory note: CJC-1295 (free base, acetate) and the CJC-1295 DAC variants were previously listed in Category 2 of the FDA's interim 503A policy. They were removed from Category 2 effective September 27, 2024, after the original nominations were withdrawn. At its December 4, 2024 meeting, the Pharmacy Compounding Advisory Committee voted against adding any CJC-1295 form to the 503A bulks list (0–13 for the free base, 1–12 for the acetate). As of October 2026, Mod GRF (1-29) / CJC-1295 (no DAC) cannot be produced by 503A compounding pharmacies and is not an FDA-approved drug. WADA prohibits it at all times as a GHRH analogue (S2.2.4).
Why Generic Peptides for Mod GRF (1-29)?
Here's a sourcing problem that's specific to Mod GRF (1-29): cheap suppliers can sell Sermorelin (unmodified GRF 1-29) labeled as Mod GRF (1-29), or partially modified material with only some of the four substitutions incorporated. The four stability substitutions are the entire reason this peptide exists. They are also easy to miss: Mod GRF (1-29) is about 3,368 Da and Sermorelin about 3,358 Da, so telling them apart needs high-resolution mass spectrometry, ideally with sequence confirmation (MS/MS). Many budget suppliers don't run that verification, which means the price gap often reflects whether the substitutions are actually there.
Generic Peptides supplies research-grade Mod GRF (1-29) for sale at 99% purity, manufactured in the USA. Domestic synthesis with all four amino acid substitutions verified — the part that determines whether you have Mod GRF or accidentally-purchased-Sermorelin pharmacology.
Order Mod GRF (1-29) for sale in the USA — 99% purity, all four substitutions verified, manufactured domestically.
Mod GRF (1-29) FAQ
Is it legal to buy Mod GRF (1-29) in the US for research?
Yes — Mod GRF (1-29) / CJC-1295 (no DAC) is legally available as a research compound in the United States. It was removed from FDA Category 2 in September 2024, but the PCAC voted against Category 1 inclusion at its December 2024 meeting, so it cannot currently be compounded by 503A pharmacies. Sales as a research compound continue legally. WADA prohibits it for tested athletes.
What's the difference between Mod GRF (1-29) and CJC-1295 DAC?
Same modified 29-amino-acid backbone. CJC-1295 DAC adds a maleimidopropionyl linker that binds serum albumin, which extended its half-life in healthy adults to roughly 6–8 days. Mod GRF (1-29) has no linker and is short-acting, though its human half-life has not been published. By mass spectrometry, Mod GRF (1-29) is about 3,368 Da and CJC-1295 DAC about 3,647 Da. More detail: CJC-1295 DAC vs No DAC.
Is Mod GRF (1-29) the same as Sermorelin?
Related but distinct. Sermorelin is unmodified GRF 1-29. Mod GRF (1-29) has four amino acid substitutions (D-Ala-2, Gln-8, Ala-15, Leu-27) that make it more resistant to enzymatic cleavage. Same active sequence, different stability. Because the two differ by only about 10 Da, verify the substitutions on the certificate of analysis.
Why is Mod GRF (1-29) typically combined with Ipamorelin?
Because they work through different receptors on the same pituitary cells. Mod GRF (1-29) activates the GHRH receptor; Ipamorelin activates the ghrelin receptor (GHS-R1a). In human studies, GHRH combined with a GH-releasing peptide produced a larger GH response than either alone, which is why researchers study the two classes together. Both are short-acting compared with CJC-1295 DAC.
I've seen this sold for half this price elsewhere — same product?
Probably not at the same purity or with all four substitutions intact. The amino acid substitutions are the technically demanding, expensive part of the synthesis. Low-cost material may be unmodified Sermorelin under the Mod GRF label, or only partially substituted. Without high-resolution mass spectrometry and sequence confirmation, the difference is invisible on the label.
Sources
Teichman SL et al. — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295." Journal of Clinical Endocrinology & Metabolism, 2006. Documents CJC-1295 receptor pharmacology and the modifications shared with the no-DAC version. https://pubmed.ncbi.nlm.nih.gov/16352683/
Alba M et al. — "Once-daily administration of CJC-1295, a long-acting GHRH analog, normalizes growth in the GHRH knockout mouse." American Journal of Physiology - Endocrinology and Metabolism, 2006. Foundational pharmacology research on CJC-1295's modified backbone. https://journals.physiology.org/doi/full/10.1152/ajpendo.00201.2006
Reed Smith (via Lexology) — "FDA removes certain peptide bulk drug substances from Category 2." Analysis of the September 2024 removal of CJC-1295 free base, acetate and DAC variants from Category 2. https://www.lexology.com/library/detail.aspx?g=2e55b76a-3173-4e04-beda-bf021202f18d
FDA — Pharmacy Compounding Advisory Committee, December 4, 2024: final summary minutes (votes on CJC-1295 free base, acetate and DAC forms). https://www.fda.gov/media/185642/download
Dominikowski A et al. — "The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis." Frontiers in Endocrinology, 2026;17:1822475. Reviews the lack of human data on CJC-1295 without DAC. https://doi.org/10.3389/fendo.2026.1822475
Bowers CY et al. — "Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone." Journal of Clinical Endocrinology & Metabolism, 1990. https://pubmed.ncbi.nlm.nih.gov/2108187/
Four substitutions. One pulse pattern. Sourcing determines whether you have Mod GRF or Sermorelin in disguise.
Mod GRF (1-29) Storage Guide: How to Keep Your Research Peptide Stable and Effective
Mod GRF (1-29), also known as CJC-1295 no DAC, ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its modified GHRH structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.
Lyophilized Powder (Unreconstituted)
| Parameter | Details | Notes |
|---|---|---|
| Storage Temperature | Freezer at −20°C (−4°F) for long-term storage up to 24 months. Refrigeration at 2–8°C (36–46°F) is fine for short-term use up to ~3 months. | Original sealed vial in the freezer is the safest default. |
| Light Sensitivity | Yes — protect from direct light and UV exposure to prevent photodegradation. | Keep in the original box or an opaque, amber container. |
| Freezing | Allowed and recommended. −20°C is standard for long-term storage; −80°C extends stability further if available. | Freeze from the start if you won't use it within 3 months. |
| Signs of Degradation | Healthy powder is white to off-white and loose or cake-like. Watch for yellowing, browning, clumping, visible moisture, or a sticky texture. | Any color change, clumping, or moisture = discard the vial. |
| Common Mistakes | Leaving the vial at room temperature after delivery, storing in a frost-free freezer with temperature swings, or opening a cold vial and letting condensation form inside. | Put it in the freezer on arrival, and let sealed vials warm to room temperature before opening. |
This guide is for informational purposes only and is not medical advice; always follow the instructions provided by your supplier.
Shipping & Product Authenticity
Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.
Shipping Times
| Destination | Delivery Time | Notes |
|---|---|---|
| USA Domestic | 2–5 business days | Faster when local warehouse stock is selected at checkout |
| International | 10–15 business days | Tracking included; update frequency may vary by destination country |
| Order Processing | 24–48 business hours | Processing begins after payment confirmation |
| Tracking | Provided on all orders | Tracking number sent after dispatch; multiple warehouses may result in separate shipments |
Direct Supply & Secure Delivery
This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.
Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.
What to Expect
- Orders are processed after payment confirmation
- USA domestic shipping is typically faster when local stock is selected
- International orders include tracking, though update frequency may vary by destination
- Multiple warehouses may result in separate shipments when applicable
Authenticity & Verified Supply
Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.
| Authenticity Feature | Details |
|---|---|
| Packaging | Original manufacturer packaging — sealed and unaltered |
| Lab Documentation | Batch-linked certificate of analysis available on request |
| Supply Chain | Sourced exclusively through official Generic Peptides distribution |
Shipping & Returns
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
<
Certificate of Analysis (COA)
Independent lab test reports are available for CJC-1295 2mg, 5mg, and 10mg batches. Each certificate provides batch-level verification details, including measured content, purity result, analysis date, and report documentation.
CJC-1295 5mg
Certificate of Analysis available
CJC-1295 10mg
Certificate of Analysis available
Click any certificate preview to enlarge the full Certificate of Analysis.
p>
Based on 8 reviews
4.8
overall
-
6
-
2
Please log in to write review.
J***s.
- March 24, 2026
The single most important thing about ordering this compound is confirming it's the No-DAC version and not CJC-1295 DAC — they get sold under overlapping names and have completely different half-lives, thirty minutes versus about a week. This vendor labels it clearly. Star off because the molecular weight on the COA is the surest way to tell them apart and it wasn't prominently stated.
Connor C
- March 11, 2026
The four substitutions are the whole point — D-Ala at position 2 to block DPP-IV, the others to stop deamidation and oxidation. Gives you a stabilized GRF(1-29) that survives extended in-vitro incubation where native sermorelin would degrade. Used it for exactly that in somatotroph signaling work. Consistent.
Thomas J
- February 22, 2026
ConjuChem developed this as the tetrasubstituted base before they added the DAC linker to make the long-acting version — so Mod GRF is essentially the intermediate that never went into serious clinical trials on its own. That history clarifies why the published data is thin for this exact compound. The listing acknowledges it. Material activated the receptor as expected.
Cameron P
- February 3, 2026
We anchor a structure-activity series with this — native sermorelin, then the tetrasubstituted Mod GRF, then the DAC version, then tesamorelin. Mod GRF is the "stabilized but still pulsatile" point on that spectrum. Each modification's effect on receptor kinetics only makes sense with the others present. Material slotted in without a vendor artifact.
O***r.
- February 2, 2026
For comparing pulsatile against sustained GHRH-receptor activation, Mod GRF is the pulsatile arm and the DAC version is the sustained arm. Sourcing both from one place with matched documentation is what makes that kinetic comparison clean. The thirty-minute versus week-long half-life contrast is the entire experiment, and vendor variability would muddy it.
Adrian P
- January 23, 2026
The DPP-IV-resistance engineering here is the same logic that runs through the modern incretin drugs — the D-Ala-2 trick to dodge the same protease. Working with Mod GRF as a GHRH example helps frame why that protection strategy is so widespread across peptide drug design. Material behaved as the pharmacology predicts.
P***n.
- January 6, 2026
Tetrasubstituted GRF(1-29) as our stabilized-pulsatile GHRH reference. Consistent batches, repeated orders. That's it.
N***a.
- December 3, 2025
Performs in somatotroph assays. Practical note: even with the four stabilizing substitutions it's still a pulsatile-kinetics compound, not long-acting — if your protocol assumed sustained activation you want the DAC version instead. We confirmed the right choice for our pulsatile design. Material was fine; just match the compound to your kinetic question.
The peptide binds GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylyl cyclase and triggering the cAMP-PKA cascade that drives GH gene transcription and release. It works upstream — telling the pituitary to make and release more of its own GH rather than supplying GH directly. The modification preserves this receptor binding while making the molecule resistant to dipeptidyl peptidase-4 cleavage.
Both are GHRH analogs targeting the same receptor with engineered stability modifications. Mod GRF (1-29) has four amino acid substitutions producing a 30-minute half-life. Tesamorelin has a single trans-3-hexenoic acid modification at the N-terminus producing a different stability profile — and it's FDA-approved for HIV-associated lipodystrophy. Different engineering strategies, different regulatory pathways.
The four amino acid substitutions specifically target the cleavage sites used by dipeptidyl peptidase-4 (DPP-4) and other peptidases that rapidly degrade native GHRH. D-Ala at position 2 alone provides significant DPP-4 resistance; the additional substitutions at positions 8, 15, and 27 protect against other enzymatic pathways. Together they produce roughly a 4-fold half-life extension.
The four amino acid substitutions are the technically demanding, expensive part of the synthesis. Cheap suppliers routinely sell unmodified Sermorelin (which has only the natural GRF 1-29 sequence) under the Mod GRF label, or produce material with only partial substitution. HPLC-MS analysis specifically targeting each modified position is required to verify all four substitutions are present.
The modified GRF backbone was developed by ConjuChem, a Canadian biotech, in the early 2000s as part of their CJC-1295 program. The four amino acid substitutions were established in the 2002-2006 timeframe, with the foundational human pharmacokinetic paper published by Teichman in 2006. The same modified backbone is used in CJC-1295 with and without DAC.
Yes. WADA prohibits CJC-1295 (with or without DAC) under category S2 (Peptide Hormones, Growth Factors, Related Substances). The classification covers the modified GRF backbone regardless of DAC status. Athletes subject to drug testing should avoid the compound regardless of how it's obtained.
CJC-1295 (no DAC), CJC-1295 free base, CJC-1295 acetate, Modified GRF 1-29, Mod GRF, and the chemical descriptor [D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]GRF(1-29). All names refer to the same modified 29-amino-acid peptide. The DAC variants are separate compounds.
Growth hormone axis pharmacology and pulsatile GH release research lead by volume. The peptide is particularly used in combination protocols with Ipamorelin or other ghrelin mimetics, where matched short half-lives produce coordinated pulses through both receptor pathways. There's also research in body composition, recovery, and aging-related GH decline using the modified GRF backbone as a research tool.
Pulse pattern preservation. Mod GRF (1-29)'s 30-minute half-life allows for pulsatile GH release that mimics natural physiology, while CJC-1295 DAC's 6-8 day half-life produces sustained baseline elevation. Researchers studying physiological GH patterns or combining with short-acting ghrelin mimetics need the no-DAC version. The DAC version is for chronic-exposure research designs.
The four amino acid substitutions provide enzymatic stability without changing the active receptor-binding region. Natural GHRH has a 7-minute half-life and produces brief, immediate GH pulses. Mod GRF (1-29) has a 30-minute half-life producing somewhat extended pulses while preserving the receptor pharmacology. The modifications are specifically designed to extend duration without altering the biological signal.
Related Products
